文献速递肿瘤 PET/CT

肯尼亚三级转诊医院复发乳腺癌患者CA 15-3与18F-FDG PET/CT表现之间的关联

Association Between CA 15-3 and 18F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya.
PubMed 文献 · J Nucl Med · 2024-10-01

该横断面回顾性研究纳入154例评估乳腺癌复发的患者,62例18F-FDG PET/CT阳性、92例阴性。CA 15-3升高与PET/CT复发及转移负荷相关,但多数PET/CT复发患者CA 15-3正常,超过一半复发患者CA 15-3在参考范围内。

要点

  • CA 15-3升高患者中84.4%(27/32)在18F-FDG PET/CT上显示复发。
  • 多数18F-FDG PET/CT复发患者CA 15-3水平正常。
  • CA 15-3在参考范围内不能排除乳腺癌复发。

核心结论

  • 较高的CA 15-3水平与18F-FDG PET/CT上的乳腺癌复发及转移负荷相关。
  • CA 15-3在参考范围内不能排除乳腺癌复发,因为超过一半复发患者CA 15-3正常。
  • 作者认为,对怀疑乳腺癌复发但CA 15-3正常的患者,应考虑行18F-FDG PET/CT。

研究设计与样本

  • 横断面研究,数据为回顾性收集。
  • 纳入因评估乳腺癌复发而接受18F-FDG PET/CT显像和CA 15-3水平检测的患者,共154例。

主要发现

  • 154例中62例18F-FDG PET/CT显示复发(阳性),92例随访18F-FDG PET/CT表现正常(阴性)。
  • CA 15-3升高患者中84.4%(27/32)在18F-FDG PET/CT上显示疾病复发,并与转移负荷相关。
  • 多数18F-FDG PET/CT显示复发的患者CA 15-3水平正常。

关键数值与推荐

  • CA 15-3升高患者中84.4%(27/32)在18F-FDG PET/CT上显示复发。
  • 超过一半的复发患者CA 15-3水平正常。

临床怎么用

  • 现行指南不推荐对根治性治疗后无症状随访患者常规检测CA 15-3,但多数肿瘤科医生将系列肿瘤标志物评估作为常规随访的一部分。
  • 作者认为,对怀疑乳腺癌复发但CA 15-3正常的患者,应考虑行18F-FDG PET/CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The tumor marker cancer antigen 15-3 (CA 15-3) is that most commonly used to monitor metastatic breast cancer during active therapy and surveillance for disease recurrence after treatment. The association of CA 15-3 and 18F-FDG PET/CT findings can be considered complementary, since any significant rise may indicate the presence of disease and imaging is able to map the tumor sites. Although current guidelines do not recommend the routine performance of CA 15-3 in asymptomatic patients being followed up after definitive breast cancer treatment, most oncologists perform serial assessment of the tumor markers as part of routine follow-up of patients. The aim of this study was to evaluate the correlation between CA 15-3 levels and 18F-FDG PET/CT scan findings in patients with recurrent breast cancer. Methods: This was a cross-sectional study with data collected retrospectively. Patients being evaluated for breast cancer recurrence with 18F-FDG PET/CT imaging and CA 15-3 level were included. Evaluation of the association between CA 15-3 levels and 18F-FDG PET/CT scan findings was then done. Results: In total, 154 cases were included in this study; 62 patients had recurrence (positive) on the 18F-FDG PET/CT scans, whereas 92 patients had normal (negative) findings on follow-up 18F-FDG PET/CT scans. There was an association between CA 15-3 levels and the presence or absence of recurrence on 18F-FDG PET/CT scans, with 84.4% (27/32) of patients who had elevated CA 15-3 levels having disease recurrence on 18F-FDG PET/CT and 84.4% (27/32) of patients who had elevated CA 15-3 levels having disease recurrence on 18F-FDG PET/CT as well as a correlation with the burden of metastases. Most patients with disease recurrence on 18F-FDG PET/CT, however, had normal CA 15-3 levels. Conclusion: Higher CA 15-3 levels correlate with breast cancer recurrence on 18F-FDG PET/CT as well as with burden of metastasis. Notably, CA 15-3 levels within the reference range do not exclude breast cancer disease recurrence since more than half of patients with recurrence had normal CA 15-3 levels. 18F-FDG PET/CT should therefore be considered in patients with suspected breast cancer recurrence but normal CA 15-3 levels.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mwania MM, Gitau SN, Shah J, et al. Association Between CA 15-3 and 18F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya. J Nucl Med. 2024. PMID: 39209543. doi:10.2967/jnumed.124.267851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。